Under the agreement, Bradley Somer will serve as Bio-Path’s Medical Officer and medical liaison for trials of liposomal Grb-2 in various forms of the disease including acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS).
Bio-Path CEO Peter Nielsen, said that: “As we prepare to enter a Phase I clinical trial for our lead liposomal antisense cancer drug, it is important that the company have access to service capabilities needed for the conduct of the trial.”
“Dr. Somer is an excellent fit to perform as Bio-Path’s Medical Officer in our Phase I clinical trial. His extensive experience in hematology and conduct of clinical trials in CML for large pharmaceutical companies will allow him to play a significant role in Bio-Path’s clinical trial.”
Bio-Path has the option of extending the deal to include more trial support, including project management, clinical data management, statistical analysis, medical and scientific writing as well as support services.
Liposomal delivery may be way forward for siRNA
Texan firm Bio-Path is developing leading edge, patented, liposomal drug delivery systems at the University of Texas. Anderson Cancer Center with two clinical cancer drug candidates ready for the clinic and a third siRNA cancer drug undergoing final pre-clinical development.
Bio-Path’s technology distributes nucleic acid drugs systemically, throughout the human body, via intravenous infusion, and can be applied both to double stranded and single stranded nucleic acid compounds.